Verona Pharma Plc Quick Ratio (VRNA) starting from the second quarter 2025 to second quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Verona Pharma Plc  (NASDAQ: VRNA)

Verona Pharma Plc's Quick Ratio

VRNA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Verona Pharma Plc's Cash & cash equivalent grew by 9.12 % in the Q2 2025 sequentially, while Current Liabilities decreased, this led to improvement in Verona Pharma Plc's Quick Ratio to 14.74, above Verona Pharma Plc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 99 other companies have achieved higher Quick Ratio than Verona Pharma Plc in second quarter 2025. While Quick Ratio total ranking has improved so far during the Q2 2025 to 320, from total ranking in the first quarter 2025 at 380.

Explain Quick Ratio?
How much Cash & cash equivalents VRNA´s has?
What are VRNA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VRNA Quick Ratio (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2
Y / Y Current Liabilities Change -38.54 % 174.3 % 717.47 % 223.65 % 364.69 %
Y / Y Cash & cash equivalent Change 8.26 % 57.49 % 47.09 % 30.57 % 49.45 %
Quick Ratio MRQ 14.74 10.72 12.45 12.02 8.37
VRNA's Total Ranking # 320 # 380 # 332 # 229 # 348
Seq. Current Liabilities Change -20.68 % 16.69 % 14.86 % -42.19 % 254.03 %
Seq. Cash & cash equivalent Change 9.12 % 0.41 % 18.96 % -16.94 % 58.74 %



Quick Ratio second quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 100
Healthcare Sector # 159
Overall Market # 320


Quick Ratio Statistics
High Average Low
36.18 12.74 2.5
(Dec 31 2023)   (Jun 30 2021)




Financial Statements
Verona Pharma Plc's Current Liabilities $ 30 Millions Visit VRNA's Balance sheet
Verona Pharma Plc's Cash & cash equivalent $ 438 Millions Visit VRNA's Balance sheet
Source of VRNA's Sales Visit VRNA's Sales by Geography


Cumulative Verona Pharma Plc's Quick Ratio

VRNA's Quick Ratio for the trailling 12 Months

VRNA Quick Ratio

 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth 70.62 % 298.27 % 183.17 % 63.18 % -7.32 %
Y / Y Cash & cash equivalent TTM Growth 32.53 % 46.18 % 27.86 % 21 % 16.34 %
Quick Ratio TTM 12.38 10.57 11.43 13.5 15.94
Total Ranking TTM # 3565 # 2904 # 2851 # 2735 # 1436
Seq. Current Liabilities TTM Growth -12.78 % 19.5 % 30.01 % 25.9 % 103.6 %
Seq. Cash & cash equivalent TTM Growth 2.17 % 10.5 % 10.1 % 6.62 % 12.69 %

Quick ratio ranking by company, industry and sector >> Back to VRNA Financial Strength Comparisons >> Go to Compare VRNA Quick Ratio to its Competitors

On the trailing twelve months basis VRNA Cash & cash equivalent improved by 8.26 % in Q2 2025 year on year, while Current Liabilities faded to $30 millions, this led to increase in in Verona Pharma Plc's Quick Ratio to 12.38, above VRNA average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 479 other companies have achieved higher Quick Ratio than Verona Pharma Plc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2025 from 2904 to 3565.

Explain Quick Ratio?
How much Cash & cash equivalents VRNA´s has?
What are VRNA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 480
Healthcare Sector # 955
Within the Market # 3565


trailing twelve months Quick Ratio Statistics
High Average Low
24.29 9.2 2.32
(Mar 31 2024)   (Dec 31 2020)




Companies with similar Quick Ratio in the quarter ending Jun 30 2025, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2025 MRQ Cash & cash equivalentJun 30 2025 MRQ Current Liabilities
Xbiotech Inc   39.65 $ 152.938  Millions$ 3.857  Millions
Roivant Sciences Ltd   39.55 $ 4,503.151  Millions$ 113.866  Millions
Apimeds Pharmaceuticals US, Inc.  36.67 $ 8.735  Millions$ 0.238  Millions
Belite Bio Inc  36.61 $ 352.932  Millions$ 9.641  Millions
Upstream Bio Inc   36.01 $ 393.581  Millions$ 10.929  Millions
Bright Minds Biosciences Inc   35.59 $ 63.669  Millions$ 1.789  Millions
Protagonist Therapeutics inc   30.59 $ 570.465  Millions$ 18.646  Millions
Edgewise Therapeutics inc   28.43 $ 593.992  Millions$ 20.896  Millions
Arca Biopharma Inc  27.12 $ 328.406  Millions$ 12.110  Millions
Inhibitor Therapeutics Inc   26.70 $ 3.738  Millions$ 0.140  Millions
Hoth Therapeutics Inc   26.26 $ 9.014  Millions$ 0.343  Millions
Viking Therapeutics Inc   25.63 $ 807.724  Millions$ 31.512  Millions
Bicara Therapeutics Inc   25.34 $ 436.606  Millions$ 17.227  Millions
Monopar Therapeutics Inc   24.94 $ 39.502  Millions$ 1.584  Millions
Design Therapeutics Inc   24.73 $ 216.276  Millions$ 8.747  Millions
Terns Pharmaceuticals Inc   24.43 $ 315.445  Millions$ 12.914  Millions
Contineum Therapeutics Inc   24.33 $ 175.484  Millions$ 7.214  Millions
Anebulo Pharmaceuticals Inc   23.84 $ 11.628  Millions$ 0.488  Millions
Fulcrum Therapeutics Inc   23.83 $ 214.111  Millions$ 8.985  Millions
Trevi Therapeutics Inc   22.77 $ 203.885  Millions$ 8.955  Millions
Rapport Therapeutics Inc   21.92 $ 260.447  Millions$ 11.879  Millions
Keros Therapeutics Inc   21.88 $ 690.215  Millions$ 31.552  Millions
Newamsterdam Pharma Company N v   21.63 $ 739.162  Millions$ 34.175  Millions
Septerna Inc   21.59 $ 326.561  Millions$ 15.127  Millions
Tyra Biosciences Inc   21.52 $ 296.271  Millions$ 13.770  Millions
Prothena Corporation Public Limited Company  21.47 $ 371.435  Millions$ 17.298  Millions
Novabridge Biosciences  21.38 $ 23.300  Millions$ 1.090  Millions
Whitehawk Therapeutics Inc   20.24 $ 177.200  Millions$ 8.756  Millions
Mbx Biosciences Inc   19.13 $ 224.906  Millions$ 11.756  Millions
Stoke Therapeutics Inc   18.96 $ 247.708  Millions$ 13.062  Millions

Date modified: 2026-09-26T07:39:03+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.